Michael Atkin
Directeur Général chez Ulysses Pharmaceuticals Products, Inc.
Profil
Michael C.
Atkin is the founder of Syzent Partners Ltd.
founded in 2008, where he holds the title of President.
He currently holds the positions of Executive Chairman, President & CEO at Ulysses Pharmaceuticals Products, Inc. and Director at Affinite Instruments.
Mr. Atkin's former positions include President & Chief Executive Officer at Aegera Therapeutics, Inc., President, Chief Executive Officer & Secretary at Gladius Pharmaceuticals Corp., Chairman at ChitogenX, Inc., Chairman at Sopharmia, Inc., Director at Genizon Biosciences, Inc., Director at Topigen Pharmaceuticals, Inc., and Principal at Bristol Myers Squibb Co. He also held the position of Vice President-Business Development at Lederle International.
Mr. Atkin received his undergraduate degree from the University of Kent and his MBA from Columbia Business School.
Postes actifs de Michael Atkin
| Sociétés | Poste | Début |
|---|---|---|
Ulysses Pharmaceuticals Products, Inc.
 Ulysses Pharmaceuticals Products, Inc. Pharmaceuticals: MajorHealth Technology Ulysses Pharmaceuticals discovers and develops antibiotics for empiric monotherapy to control resistant bacterial infections. The company was founded in December 2001 by Suzanne Chamberland, Roger Léger, and François Malouin and is headquartered in Sherbrooke, Canada | Directeur Général | - |
| Syzent Partners Ltd. | Fondateur | 01/01/2008 |
| Affinite Instruments | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael Atkin
| Sociétés | Poste | Fin |
|---|---|---|
| CHITOGENX INC. | Président | 01/07/2022 |
Gladius Pharmaceuticals Corp.
 Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Directeur Général | 01/01/2019 |
Genizon Biosciences, Inc.
 Genizon Biosciences, Inc. BiotechnologyHealth Technology Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry. | Directeur/Membre du Conseil | 30/05/2012 |
| Sopharmia, Inc. | Président | - |
| Lederle International | Corporate Officer/Principal | - |
Formation de Michael Atkin
| University of Kent | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| CHITOGENX INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Genizon Biosciences, Inc.
Genizon Biosciences, Inc. BiotechnologyHealth Technology Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry. | Health Technology |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Health Technology |
Topigen Pharmaceuticals, Inc.
 Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topigen Pharmaceuticals, Inc. develops drugs for respiratory diseases. The firm focuses on discovery and development of multiple pathway therapies for respiratory diseases with primary emphasis on asthma, chronic obstructive pulmonary disease, and allergic rhinitis. The company was founded by Paolo Renzi in 2000 and is headquartered in Montréal, Canada. | Health Technology |
| Lederle International | |
Ulysses Pharmaceuticals Products, Inc.
Ulysses Pharmaceuticals Products, Inc. Pharmaceuticals: MajorHealth Technology Ulysses Pharmaceuticals discovers and develops antibiotics for empiric monotherapy to control resistant bacterial infections. The company was founded in December 2001 by Suzanne Chamberland, Roger Léger, and François Malouin and is headquartered in Sherbrooke, Canada | Health Technology |
Gladius Pharmaceuticals Corp.
Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Health Technology |
| Syzent Partners Ltd. | |
| Sopharmia, Inc. | |
| Affinite Instruments |